4:44 PM
 | 
Apr 18, 2019
 |  BC Extra  |  Company News

Three steps forward, one step back for AI drug discovery

Two AI drug discovery and development deals this week, and new hits announced from an existing collaboration, show sustained momentum in the space despite news that IBM will stop seeking partnerships for its Watson for Drug Discovery platform.

In the newest deal, announced Thursday morning, twoXAR Inc. (Mountain View, Calif.) will use its AI discovery technology to identify non-small cell lung cancer (NSCLC) therapeutics with new mechanisms of...

Read the full 316 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >